Gerretsen, Philip
Rajji, Tarek K.
Shah, Parita
Shahab, Saba
Sanches, Marcos
Graff-Guerrero, Ariel
Menon, Mahesh
Pollock, Bruce G.
Mamo, David C.
Mulsant, Benoit H.
Voineskos, Aristotle N.
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Centre for Addiction and Mental Health
Article History
Received: 25 October 2018
Accepted: 19 March 2019
First Online: 29 April 2019
Competing interests
: Dr. Gerretsen reports receiving research support from the Canadian Institutes of Health Research (CIHR), Ontario Ministry of Health and Long-Term Care, Ontario Mental Health Foundation (OMHF), and the Centre for Addiction and Mental Health (CAMH). Dr. Rajji reports receiving during the past five years research support from Brain Canada, Brain and Behavior Research Foundation, CAMH Foundation, Canada Foundation for Innovation, Canada Research Chair, Canadian Institutes of Health Research (CIHR), Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, the US National Institute of Health (NIH), and the Weston Brain Institute. Ms. Shah reports receiving CIHR Canadian Graduate Scholarship–Master’s. Ms. Shahab reports receiving Ontario Graduate Scholarship. Mr. Sanches, Drs. Pollock and Mamo report no conflict of interest. Dr. Graff-Guerrero reports receiving support from the United States National Institute of Health, CIHR, OMHF, Consejo Nacional de Ciencia y Tecnología, the Instituto de Ciencia y Tecnología del DF, the Brain & Behavior Research Foundation (Formerly NARSAD), the Ontario Ministry of Health and Long-Term Care, the Ontario Ministry of Research and Innovation Early Research Award, and Janssen. Dr. Menon has received research funding from the Canadian Institutes of Health Research (CIHR), Ontario Mental Health Foundation (OMHF), the Centre for Addiction and Mental Health (CAMH), the MIND Foundation and the Vancouver Coastal Health Research Institute. Dr. Mulsant currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the US National Institute of Health (NIH), Eli Lilly (medications for a NIH-funded clinical trial), Pfizer (medications for a NIH-funded clinical trial), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). Within the past five years he has also received research support from BristolMyers Squibb (medications for a NIH-funded clinical trial) and Pfizer/Wyeth (medications for a NIH-funded clinical trial). He directly own stocks of General Electric (< $5000). Dr. Voineskos receives funding from the Canadian Institutes of Health Research, Ontario Mental Health Foundation, Canada Foundation for Innovation, Brain and Behavior Research Foundation, CAMH Foundation, and the National Institute of Mental Health (R01MH099167 and R01MH102324).